{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:50:50Z","timestamp":1777596650866,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1023\/a:1019905111666","type":"journal-article","created":{"date-parts":[[2003,3,15]],"date-time":"2003-03-15T13:06:10Z","timestamp":1047733570000},"page":"249-258","source":"Crossref","is-referenced-by-count":75,"title":["The Effect of the Bisphosphonate Ibandronate on Breast Cancer Metastasis to Visceral Organs"],"prefix":"10.1007","volume":"75","author":[{"given":"Toshimi","family":"Michigami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Hiraga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Niewolna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R.","family":"Mundy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5091617_CR1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H Fleish","year":"1998","unstructured":"Fleish H: Bisphosphonates: mechanism of action. Endocrine Rev 19: 80\u2013100, 1998","journal-title":"Endocrine Rev"},{"key":"5091617_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1993.11.3.491","volume":"11","author":"ATM Van Holten-Verzantvoort","year":"1993","unstructured":"Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans Neijt JP, Papapoulos SE, Sleeboom HP, Vermey P, Zwinderman AH: Palliative pamidronate treatment in patients with bone metas-tases from breast cancer. J Clin Oncol 11: 491\u2013498, 1993","journal-title":"J Clin Oncol"},{"key":"5091617_CR3","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","volume":"335","author":"GN Hortobagyi","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of pamidronate in reducing skeletal complications in-patients with breast cancer and lytic bone metastases. N Engl J Med 335: 1785\u20131791, 1996","journal-title":"N Engl J Med"},{"key":"5091617_CR4","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1200\/JCO.1998.16.12.3890","volume":"16","author":"JJ Body","year":"1998","unstructured":"Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD: Current use of bisphosphonates in oncology. J Clin Oncol 16: 3890\u20133899, 1998","journal-title":"J Clin Oncol"},{"key":"5091617_CR5","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199808063390609","volume":"339","author":"GR Mundy","year":"1998","unstructured":"Mundy GR, Yoneda T: Bisphosphonates as anticancer drugs. N Engl J Med 339: 398\u2013400, 1998","journal-title":"N Engl J Med"},{"key":"5091617_CR6","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ: Pamidro-nate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol 17: 846\u2013854, 1999","journal-title":"J Clin Oncol"},{"key":"5091617_CR7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Bastert G: Reduction in new metastases in breast cancer with adjuvant clodronate treat-ment. N Engl J Med 339: 357\u2013363, 1998","journal-title":"N Engl J Med"},{"key":"5091617_CR8","unstructured":"Diel IJ, Solomayer E-F, Gollan C, Shutz F, Bastert G: Bisphosphonates in the reduction of metastases in breast cancer \u2013 results of the extended follow-up of the first study population. Proceedings ASCO Abst # 314, 2000"},{"key":"5091617_CR9","first-page":"S189","volume":"23","author":"EV McCloskey","year":"1998","unstructured":"McCloskey EV, Powles T, Paterson AHG, Ashley S, Kanis JA: Clodronate reduces incidence of skeletal metastases in women with primary breast cancer. Bone 23: S189, 1998","journal-title":"Bone"},{"key":"5091617_CR10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","volume":"19","author":"T Saarto","year":"2001","unstructured":"Saarto T, Blomqvist C, Virkkunen P, Elomaa II: adjuvant clo-dronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 19: 10\u201317, 2001","journal-title":"J Clin Oncol"},{"key":"5091617_CR11","first-page":"5452","volume":"53","author":"PJ Kostenuik","year":"1993","unstructured":"Kostenuik PJ, Orr FW, Suyama K, Orr FW: Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 53: 5452\u20135457, 1993","journal-title":"Cancer Res"},{"key":"5091617_CR12","first-page":"3551","volume":"55","author":"A Sasaki","year":"1995","unstructured":"Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T: Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55: 3551\u20133557, 1995","journal-title":"Cancer Res"},{"key":"5091617_CR13","first-page":"116","volume":"16","author":"ME Stearns","year":"1996","unstructured":"Stearns ME, Wang M: Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invasion Metast 16: 116\u2013131, 1996","journal-title":"Invasion Metast"},{"key":"5091617_CR14","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U","volume":"88","author":"T Yoneda","year":"2000","unstructured":"Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T: Actions of bisphosphonate on bone metastasis in animal models of breast cancer. Cancer 88: 2979\u20132988, 2000","journal-title":"Cancer"},{"key":"5091617_CR15","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI119435","volume":"99","author":"T Yoneda","year":"1997","unstructured":"Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR: Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 99: 2509\u20132517, 1997","journal-title":"J Clin Invest"},{"key":"5091617_CR16","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson CJ, Fred R Miller: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399\u20131405, 1992","journal-title":"Cancer Res"},{"key":"5091617_CR17","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jnci\/53.3.661","volume":"53","author":"R Cailleau","year":"1974","unstructured":"Cailleau R, Young R, Olive M, Reeves WJ Jr: Breast tu-mor cell line from pleural effusions. J Natl Cancer Inst 53: 661\u2013674, 1974","journal-title":"J Natl Cancer Inst"},{"key":"5091617_CR18","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1359\/jbmr.2001.16.8.1486","volume":"16","author":"T Yoneda","year":"2001","unstructured":"Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R: A bone-seeking subclone exhibits different properties from the parental MDA-MB-231 human breast cancer cells and a brain-seeking subclone in vivo and in vitro. J Bone Miner Res 16: 1486\u20131495, 2001","journal-title":"J Bone Miner Res"},{"key":"5091617_CR19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/1097-0142(195905\/06)12:3<521::AID-CNCR2820120311>3.0.CO;2-B","volume":"12","author":"G Lumb","year":"1959","unstructured":"Lumb G, Mackenzie DH: The incidence of metastases in ad-renal glands and ovaries removed for carcinoma of the breast. Cancer 12: 521\u2013526, 1959","journal-title":"Cancer"},{"key":"5091617_CR20","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","volume":"6","author":"RC Muhlbauer","year":"1991","unstructured":"Muhlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6: 1003\u20131011, 1991","journal-title":"J Bone Miner Res"},{"key":"5091617_CR21","first-page":"4418","volume":"61","author":"T Hiraga","year":"2001","unstructured":"Hiraga T, Williams PJ, Mundy GR, Yoneda T: The bisphos-phonate ibandronate promotes apoptosis in MDA-231 hu-man breast cancer cells in bone metastases. Cancer Res 61: 4418\u20134424, 2001","journal-title":"Cancer Res"},{"key":"5091617_CR22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1053\/ctrv.1999.0137","volume":"25","author":"N Kroger","year":"1999","unstructured":"Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander AR: Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev 25: 279\u2013291, 1999","journal-title":"Cancer Treat Rev"},{"key":"5091617_CR23","doi-asserted-by":"crossref","first-page":"12665","DOI":"10.1016\/S0021-9258(18)67143-1","volume":"261","author":"PV Hauschka","year":"1986","unstructured":"Hauschka PV, Mavrokos AE, Lafrati MD, Doleman SE, Klagsbrun M: Growth factors in bone matrix. Isolation of mul-tiple types by affinity chromatography on heparin-sepharose. J Biol Chem 261: 12665\u201312674, 1986","journal-title":"J Biol Chem"},{"key":"5091617_CR24","first-page":"41","volume-title":"Tumor Bone Dis-eases and Osteoporosis in Cancer Patients","author":"T Yoneda","year":"2000","unstructured":"Yoneda T, Williams PJ, Myoi A, Michigami T, Mbalaviele G: Cellular and molecular mechanisms of development of skeletal metastases. In: Body J-J (ed.) Tumor Bone Dis-eases and Osteoporosis in Cancer Patients. Marcel Dekker, New York, 2000, pp 41\u201369"},{"key":"5091617_CR25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","volume":"98","author":"G Van der Pluijm","year":"1996","unstructured":"Van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C: Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98: 698\u2013705, 1996","journal-title":"J Clin Invest"},{"key":"5091617_CR26","first-page":"3890","volume":"57","author":"S Boisser","year":"1997","unstructured":"Boisser S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineral-ized bone extracellular matrices. Cancer Res 57: 3890\u20133894, 1997","journal-title":"Cancer Res"},{"key":"5091617_CR27","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","volume":"18","author":"BE Hillner","year":"2000","unstructured":"Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, Yee G, Biermann JS, Chlebowski RT, Pfister DG: American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18: 1378\u20131391, 2000","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1019905111666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1019905111666\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/A:1019905111666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1019905111666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:25:11Z","timestamp":1750479911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1019905111666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["5091617"],"URL":"https:\/\/doi.org\/10.1023\/a:1019905111666","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}